Home › Funds › BlackRock › iShares U.S. Pharmaceuticals ETF
Fund family: BlackRock · Filed by iSHARES TRUST (CIK 1100663) · SEC series S000009417
Ticker: IHE (C000025771)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 442 with, 12 against, 6 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 9 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as BlackRock’s manager page (1,606,521 ballot items across 392 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | BlackRock | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 96.6% | 441 | 93.6% | 1,355,861 |
| Backed environmental and social shareholder proposals at US companies | n/a | 2 | 5.5% | 6,306 |
Each ballot item this fund voted is set against the votes of the other BlackRock funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most BlackRock funds on all 453 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 95.4% of this fund’s 460 such votes could be given a sector; the other 21 (4.6%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 428 | 12 | 2.8% |
| Industrials | 11 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 303 | 3 |
| Audit-related | 57 | 0 |
| Say-on-Pay | 56 | 0 |
| Compensation | 19 | 0 |
| Corporate Governance | 13 | 6 |
| Capital Structure | 12 | 0 |
| Shareholder Rights and Defenses | 4 | 1 |
| Other Social Issues | 2 | 2 |
| Extraordinary Transactions | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| ELI LILLY AND COMPANY | May 4, 2026 | $313M | 10 | 2 |
| JOHNSON & JOHNSON | April 23, 2026 | $296M | 15 | 1 |
| VIATRIS INC. | May 15, 2026 | $63M | 15 | 0 |
| MERCK & CO., INC. | May 26, 2026 | $57M | 18 | 3 |
| BRISTOL-MYERS SQUIBB COMPANY | May 5, 2026 | $53M | 15 | 1 |
| VIATRIS INC. | December 5, 2025 | $52M | 15 | 0 |
| PFIZER INC. | April 23, 2026 | $49M | 16 | 1 |
| ZOETIS INC. | May 20, 2026 | $32M | 16 | 1 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | ELI LILLY AND COMPANY | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | ELI LILLY AND COMPANY | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 23, 2026 | JOHNSON & JOHNSON | Independent Board Chair Shareholder proposal | Against | For |
| May 26, 2026 | MERCK & CO., INC. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | MERCK & CO., INC. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 5, 2026 | BRISTOL-MYERS SQUIBB COMPANY | Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposal | Against | For |
| April 23, 2026 | PFIZER INC. | Adopt an Independent Chair Policy Shareholder proposal | Against | For |
| May 20, 2026 | ZOETIS INC. | Shareholder proposal to permit shareholder action by written consent. Shareholder proposal | Against | For |
| June 9, 2026 | PACIRA BIOSCIENCES, INC. | DOMA Nominees Opposed by the Company: Oliver Benton Curtis III | Withhold | For |
| June 9, 2026 | PACIRA BIOSCIENCES, INC. | DOMA Nominees Opposed by the Company: Eric de Armas | Withhold | For |
Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.
467 ballot items at 58 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, iShares U.S. Pharmaceuticals ETF (IHE) voted at 58 shareholder meetings of 56 companies, on 467 ballot items in all. Where management made a recommendation, the fund followed it on 96.1% of the items and voted against it 12 times. Its most frequent area of disagreement was corporate governance (6 of its votes against management). It voted on 9 shareholder proposals. It voted FOR the board's own proposals more often than BlackRock's funds as a whole (96.6% against 93.6%). It voted the same way as most BlackRock funds on every item where a comparison was possible. 1 of its meetings was contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of BlackRock’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.